Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Salt Lake City, Utah 84112


Purpose:

The cardiovascular effects of vitamin D therapy (in humans) have been documented only in patients with known vitamin D deficiency or hyperparathyroidism (a surrogate marker of inadequate vitamin D activity). It is unknown whether the cardiovascular benefits of vitamin D therapy extend beyond these patients to the general hypertensive population. We propose to directly measure the effect of vitamin D therapy on plasma renin activity (PRA), plasma renin concentration (PRC), renin transcription (in mononuclear leukocytes), and blood pressure in hypertensive (but otherwise healthy) patients in a randomized, controlled, experimental trial. This will be the first study to assess vitamin D receptor (VDR) biological (PRA, PRC, renin mRNA, and polymorphisms) and hypertensive activity in patients without vitamin D deficiency. We hypothesize that vitamin D inhibition of renin transcription will produce significant reductions in PRA, PRC, renin transcription, inflammatory cytokines, SBP, and DBP, with potential variation by VDR genotype. Such a result may prove to be significant in the treatment of hypertension, as even modest blood pressure reductions (5 mmHg) are associated with a 14% reduction in mortality due to stroke, a 9% reduction in mortality due to CHD, and a 7% overall reduction in all-cause mortality.


Criteria:

Inclusion Criteria: 1. Male or female patients age > 55 years. 2. Female patients must be postmenopausal, as determined by surgical hysterectomy or 12 month history since last active menstruation 3. Stage I hypertension (JNC VII Criteria): mean systolic blood pressure (mSBP) 140-159 mmHg and mean diastolic blood pressure 90 - 99 mmHg (mDBP)2 4. Provide informed consent Exclusion Criteria: 1. Serum vitamin D <55 pmol/L 2. Serum calcium >10.5 mg/dL 3. Serum phosphate (inorganic) >5.5 mg/dL 4. Serum parathyroid hormone (PTH) >1.3 pmol/L 5. Vitamin D supplements, calcium supplements, estrogen replacement therapy, corticosteroids (inhaled/oral), or hydroxymethyl glutarate CoA reductase inhibitors (statins) within 30 days prior to randomization 6. Stage II hypertension (JNC VII criteria): mSSBP >160 mmHg or mSDBP >100 mmHg 7. Use of alpha2-agonists, beta-blockers, or more than 2 anti-hypertensive medications at screening 8. Estimated creatinine clearance <30 mL/min by Crockroft-Gault Formula 9. History of heart failure (HF), acute myocardial infarction (AMI), acute coronary syndrome (ACS), transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral vascular disease (PVD), or known clotting disorder 10. Insulin dependent diabetes mellitus (patients stabilized on oral regimens may be enrolled) 11. History of hypersensitivity reaction to 1α, 25-(OH)2 vitamin D3 (calcitriol)


NCT ID:

NCT00585442


Primary Contact:

Principal Investigator
Mark Munger, PharmD
University of Utah


Backup Contact:

N/A


Location Contact:

Salt Lake City, Utah 84112
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.